| dc.creator |
Gurlek, Beril |
|
| dc.creator |
Kazaz, Ilknur M. |
|
| dc.creator |
Durakoglugil, Murtaza E. |
|
| dc.creator |
Karakas, Sibel |
|
| dc.creator |
ÖNAL, Özgür |
|
| dc.creator |
Satiroglu, Omer |
|
| dc.creator |
Yilmaz, Adnan |
|
| dc.date |
2019-12-31T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T09:25:02Z |
|
| dc.date.available |
2020-10-06T09:25:02Z |
|
| dc.identifier |
0fe0f829-1e27-41ea-bf6a-8aaca1ca404f |
|
| dc.identifier |
10.1111/jog.14137 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/0fe0f829-1e27-41ea-bf6a-8aaca1ca404f/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/53458 |
|
| dc.description |
Aim Recent studies suggest that apelin can be a novel potential therapeutic mediator to improve the diagnosis, and treatment of preeclampsia. This study aimed to investigate the association of serum apelin-13 and apelin-36 with preeclampsia and to detect their relationship with preeclampsia-associated perinatal morbidity. Methods Forty-four women with preeclampsia were included as the study group. Forty-four healthy pregnant women, at similar gestational week with similar gravidity, formed the control group. The clinical findings, biochemical indicators, maternal and perinatal outcomes, and the serum concentrations of apelin-36 and apelin-13 were evaluated. The levels of apelin-13 and apelin-36 were determined with commercial kits using a competition-based enzyme-linked immunosorbent assay method. Results The mean gestational age at sampling was 35.77 +/- 2.515 weeks in the preeclamptic group, 36.45 +/- 2.057 weeks in the control group (P = 0.270). Maternal serum apelin-36 and apelin-13 concentrations were significantly lower in patients with preeclampsia compared to the individuals in the control group (P = 0.030 and P = 0.005, respectively). The optimal cut-off points of apelin-36 and apelin-13 measurements for discriminating between preeclampsia and controls were evaluated by the receiver-operator curve analysis. The results showed that apelin-13 and apelin-36 are moderately successful markers to differentiate subjects with preeclampsia from healthy pregnant women. The concentrations of apelin-13 and apelin-36 in both groups were not statistically different in cases with and without adverse fetal/neonatal outcomes. Conclusion In conclusion, we investigated serum apelin-13 and apelin-36 concentrations in preeclamptic patients and demonstrated markedly lower maternal concentrations compared to healthy pregnant women. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Evaluation of serum apelin-13 and apelin-36 concentrations in preeclamptic pregnancies |
|
| dc.type |
info:eu-repo/semantics/article |
|